Elisa Arthofer

Elisa Arthofer has an extensive work experience in the field of biotechnology. Elisa began their career as a Research Fellow at Harvard University's The Harvard Stem Cell Institute in 2011, where they focused on the generation of patient and disease-specific induced pluripotent stem cells (iPSCs) from human fibroblasts. In 2012, they became a PhD Candidate at Karolinska Institutet, exploring the WNT/Frizzled signaling pathway in mammals. In 2014, they were a Visiting Research Fellow and PhD Candidate at the National Institutes of Health's National Institute of Dental and Craniofacial Research. In 2015, they became a Postdoctoral Fellow at the National Institutes of Health, where they studied the epigenetic regulation of immune signaling in cancer. From 2017 to 2019, they were a Postdoctoral Scientist at The George Washington University School of Medicine and Health Sciences. During this time, they worked with syngeneic mouse models for cancer, immunology and T cell biology, CRISPR/Cas9 gene editing in cancer cells, epigenetic modulation of cancer cells, and TP53 hotspot mutations in cancer. In 2019, they became a Scientist - Gene Editing Lead for Immuno-Oncology and Autoimmunity at Precigen. In 2019, they were also a Member of the Board of Directors and Vice-President at ASciNA - Austrian Scientists and Scholars in North America, where they fostered existing and created new relationships and professional connections with Austrian professionals and delegates in Washington DC and the Austrian Office of Science and Technology (OSTA). In 2020, they became a Team Leader and Principal Scientist at Intima Bioscience, where they oversaw and ensured progress for all research and development activities feeding into the pre-clinical development of Intima's Immuno-Oncology portfolio. Elisa also scouted talent to expand the I/O R&D team from 2 to 7 scientists, resulting in a successful $60M Series C in 2021. In 2022, they became a Founder, Enabling Immunotherapies in Solid Tumors at Deep Science Ventures, and a Director at wildside bio.

Elisa Arthofer holds a Doctor of Philosophy - PhD in Medical Science - Pharmacology from Karolinska Institutet, a Master of Science (MSc) in Medical & Pharmaceutical Biotechnology from IMC University of Applied Sciences Krems, a Bachelor of Science (BSc) in Medical & Pharmaceutical Biotechnology from IMC University of Applied Sciences Krems, and a MLBT in Legal and business aspects in technics from Johannes Kepler Universität Linz.